{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FF%2FGW642444+Inhalation+Powder", "query": { "intervention": "FF/GW642444 Inhalation Powder" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FF%2FGW642444+Inhalation+Powder&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T03:46:59.338Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01009463", "title": "A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF/GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "GW642444 Inhalation Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1626, "start_date": "2009-09-25", "completion_date": "2011-10-31", "has_results": true, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 94, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01009463" }, { "nct_id": "NCT01323621", "title": "Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate 250mcg / salmeterol 50mcg", "type": "DRUG" }, { "name": "Double-dummy placebo", "type": "DRUG" }, { "name": "Salbutamol as needed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 512, "start_date": "2011-03-18", "completion_date": "2012-01-24", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 13, "location_summary": "Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Riverside", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323621" }, { "nct_id": "NCT01323634", "title": "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate 250mcg/ salmeterol 50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 519, "start_date": "2011-03-18", "completion_date": "2011-12-14", "has_results": true, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 12, "location_summary": "Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323634" }, { "nct_id": "NCT01086410", "title": "Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Placebo Inhalation Powder", "type": "DRUG" }, { "name": "Fluticasone Furoate/GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "Placebo Oral Capsule", "type": "DRUG" }, { "name": "Prednisolone Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 185, "start_date": "2010-03", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 4, "location_summary": "Cypress, California • Huntington Beach, California • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01086410" }, { "nct_id": "NCT01054885", "title": "Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF Inhalation Powder", "type": "DRUG" }, { "name": "FF/GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1226, "start_date": "2009-10-19", "completion_date": "2011-02-08", "has_results": true, "last_update_posted_date": "2018-01-24", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Lakewood, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Lakewood", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01054885" }, { "nct_id": "NCT01053988", "title": "A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF/GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "FF Inhalation Powder", "type": "DRUG" }, { "name": "GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1031, "start_date": "2009-10-05", "completion_date": "2011-04-14", "has_results": true, "last_update_posted_date": "2018-07-12", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 47, "location_summary": "Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 42 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01053988" }, { "nct_id": "NCT01072149", "title": "A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate (FF)/GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "placebo", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 54, "start_date": "2010-01-01", "completion_date": "2010-07-01", "has_results": true, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 8, "location_summary": "DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more", "locations": [ { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01072149" }, { "nct_id": "NCT01017952", "title": "A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF/GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "GW642444 Inhalation Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1635, "start_date": "2009-09-25", "completion_date": "2011-10-17", "has_results": true, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Ozark", "state": "Alabama" }, { "city": "Tallassee", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01017952" }, { "nct_id": "NCT03248128", "title": "Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FF/VI via ELLIPTA DPI", "type": "DRUG" }, { "name": "FF via ELLIPTA DPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 906, "start_date": "2017-10-20", "completion_date": "2022-03-21", "has_results": true, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 49, "location_summary": "Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more", "locations": [ { "city": "Hoover", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03248128" }, { "nct_id": "NCT01894386", "title": "Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF 400 mcg", "type": "DRUG" }, { "name": "UMEC 500 mcg", "type": "DRUG" }, { "name": "UMEC 250 mcg", "type": "DRUG" }, { "name": "VI 100 mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2013-07-15", "completion_date": "2013-09-26", "has_results": false, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-09-14T03:46:59.338Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01894386" } ] }